{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.03","upperLimit":"5.75","value":"2.79"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"description":"Time from first study drug intake to first MMR amongst imatinib or dasatinib resistant or intolerant patients with CML-CP computed only for patients who achieved MMR.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients resistant or intolerant to either imatinib or dasatinib","id":"OG000","title":"Resistant/Intolerant Ph+ CML in CP"}],"paramType":"MEDIAN","populationDescription":"Full Analysis Set (FAS): All patients who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"From first dosing to the first MMR within 66 cycles period","title":"Time to First MMR Among Imatinib or Dasatinib Resistant or Intolerant CML-CP Patients Who Achieved MMR","type":"SECONDARY","unitOfMeasure":"months"}